Key facts
- Remedy Meds’s last known valuation is $30.9M (Nov 2025).
- It has raised $2.9M; the latest was Seed Round ($2.9M) in Nov 2025.
- Notable investors include HealthQuest Capital, Gurtin Ventures, Dynamism Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Remedy Meds
- ·The full record, as it builds
Funding rounds
No funding rounds for Remedy Meds are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Remedy Meds
Provider of a telehealth service intended to facilitate weight loss. The company offers a platform that connects individuals with partner clinicians for prescriptions, provides unlimited telehealth visits, ensures access to compounded glucagon-like peptide medications from pharmacies without insurance requirements or waitlists, and offers ongoing clinical support, enabling patients to receive weight loss treatment conveniently and transparently.
- Sector
- Healthcare
- HQ
- Short Hills, NJ, United States
- Founded
- 2024
- Website
- remedymeds.com/
- Ownership
- Privately Held (backing)
Remedy Meds doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Remedy Meds shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Remedy Meds in its N-PORT filings yet. We sweep new filings monthly.